Loading
Inhibitory KIRs are the receptors NK cells use to recognise a person's own HLA-C and stand down. Lirilumab, an antibody that blocks three of them, reached phase 2 but was dropped for blood cancers. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Immunoglobulin-like receptors with long cytoplasmic tails (2DL, 3DL) inhibit through ITIMs; short-tailed KIRs activate. This record stands for the inhibitory KIR2DL group the antibody binds.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"KIR2DL1" OR ABSTRACT:"KIR2DL1" OR TITLE:"inhibitory KIR" OR ABSTRACT:"inhibitory KIR" OR TITLE:"KIR" OR ABSTRACT:"KIR" OR TITLE:"CD158a" OR ABSTRACT:"CD158a" OR TITLE:"p58.1" OR ABSTRACT:"p58.1" OR TITLE:"KIR2DL2" OR ABSTRACT:"KIR2DL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KIR2DL1 (inhibitory KIR), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/kir2dl1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/kir2dl1.json. Licence CC BY-NC 4.0.